PulseCath B.V. develops, manufactures and markets minimal invasive circulatory support systems which are safe, effective, and very cost effective.
Pulsecath’s iVAC 3L™ is a mid-range left ventricukar assist device that generates a bloodflow of up to 3L/min. The lead product, the iVAC 2L™, generates approxymately 2.5 L/min and can be inserted through the femoral artery.
Portfolio: MedSciences Seed Fund B.V. and MedSciences Capital II B.V.
Current product development stage: CE mark and market introduction (iVAC 3L™) and clinical study for CE mark (iVAC 2L™).